pelabresib

pelabresib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Malignancies and Hepatic Impairment、Primary Myelofibrosis (PMF)、Post-polycythemia Vera Myelofibrosis (PPV-MF)、Post-essential Thrombocythemia Myelofibrosis (PET-MF)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 pelabresib 研究

• A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

  I 期招募中法国意大利西班牙NCT07340190

• An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

  III 期招募中美国比利时意大利荷兰NCT06401356

• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  III 期招募中美国Argentina澳大利亚奥地利NCT07357727

• A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants

  I 期招募中英国NCT07783503

• Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

  I 期招募中法国意大利西班牙英国NCT07422610

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。